Computer artwork of monoclonal antibodies,bi-specific T-cell engagers (BiTEs),acting against tumour cells. Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia. The image shows a cancer cell (red,down left) and an immune cell (blue,upper right) connected by the Blinatumomab bi-specific antibody | |
Lizenzart: | Lizenzpflichtig |
Credit: | Science Photo Library / Pasieka, Alfred |
Bildgröße: | 3750 px × 5000 px |
Modell-Rechte: | nicht erforderlich |
Eigentums-Rechte: | nicht erforderlich |
Restrictions: | - |